Company profilePharmaceutical#39 of 1,318 in Pakistan1 DRAP alert

Amarant Pharmaceuticals Private Limited

Pharmaceutical company · 261 brands · 242 molecules

Ranked #4 of 62 companies in Neuro

261 registered products 72 pharmaceutical brands 242 distinct molecules 1 DRAP alert

Company overview

261
registered products
72
pharmaceutical brands
242
distinct molecules
12
therapeutic classes
1
DRAP alerts

Amarant Pharmaceuticals Private Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 261 product registrations across 242 distinct molecules. It is the 39th largest registrant in Pakistan by product count, and ranks 4th of 62 in Neuro. Its portfolio is concentrated in Neuro and Antidepressants. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Amarant

184 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

137
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20255
2026132

Top molecules by brand count

Amlodipine10 brands
Artemether9 brands
Cefixime6 brands
Risperidone6 brands
Metformin6 brands
Paracetamol6 brands
Bupropion5 brands
Famotidine5 brands
Azithromycin5 brands
Ceftriaxone5 brands

Therapeutic classes

Neuro · 13Antidepressants · 9Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Antiepileptics · 5Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 5Gastro · 4Antiinflammatory And Antirheumatic Products · 4Antiemetics & Antinauseants · 4Opioids · 4Antianemic, Iron Preparations · 4Angiotensin-Ii Antagonists, Combinations · 3Other Nervous System Drugs · 3

Conditions treated

Anxiety/Depression/Insomnia · 5Epilepsy/Convulsion · 3Ulcer/Reflux/Flatulence/Acidity · 2Intestinal & Bowel Syndrome · 2Schizophrenia/Psychosis · 2Migraine/Vertigo · 1Neuropathic Pain/Epilepsy/Convulsion · 1Alzheimer`S · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official228 products · Rs 18.01 – Rs 11,525.21
DVAGO53 products · Rs 99.59 – Rs 1,516.2
Servaid27 products · Rs 111.96 – Rs 1,932
Median across source: Rs 356.3

Regulatory record

1 alert in the DRAP feed we track.

Precautionary Recall of Inj. Cara-Fer (Iron Sucrose 100mg/5ml), Batch No. 24G001
2025-09-12

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 95 molecules not in this portfolio
000 I.UAremetherArtesunateAscorbic AcidAtorvastatinAzathioprine
GENOME PHARMACEUTICALS (PVT) LTD holds 70 molecules not in this portfolio
AcitretinAnastrazoleAnastrozoleArtesunateBisoprololCalcium
GETZ PHARMA PAKISTAN (PVT) LTD. holds 212 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole

Get the full profile for Amarant

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.